Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kallyope

Kallyope?uq=3Oe4kK1Z
2014 FOUNDED
PRIVATE STATUS
31-40 EMPLOYEES
Series B LATEST DEAL TYPE
$87M LATEST DEAL AMOUNT
11 INVESTORS
Description

Operator of a biotechnology platform intended to unlock the therapeutic and nutritional product potential of the gut-brain axis to improve human health. The company's biotechnology platform integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology and human genetics, enabling the healthcare industry to understand gut-brain biology that will lead to transformational therapeutics to improve human health and nutrition.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 430 East 29th Street
  • 10th Floor
  • New York, NY 10016
  • United States

+1 (646) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kallyope’s full profile, request a free trial.

Kallyope Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 05-Dec-2018 $87M 00000 00000 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2015 0000 0000 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Kallyope Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00 00 00 00 000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Kallyope Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Columbia Technology Ventures University Minority 000 0000 000000 0
Euclidean Capital Other Minority 000 0000 000000 0
Two Sigma Ventures Venture Capital Minority 000 0000 000000 0
William Gates Angel (individual) Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Kallyope Executive Team (6)

Name Title Board
Seat
Contact
Info
Nancy Thornberry Chief Executive Officer & Board Member
Charles Zuker Ph.D Co-Founder
Richard Axel MD Co-Founder
Ann Weber Ph.D Senior Vice President - Drug Discovery
Robert Anstey Vice President, Business Development
You’re viewing 5 of 6 executives. Get the full list »

Kallyope Board Members (8)

Name Representing Role Since Contact
Info
Amy Schulman JD Polaris Partners Board Member 000 0000
Joshua Wolfe Lux Capital Board Member 000 0000
Nancy Thornberry Kallyope Chief Executive Officer & Board Member 000 0000
Terry McGuire Self Board Member & Strategic Advisor 000 0000
Timothy Kutzkey Ph.D The Column Group Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »